CLYM vs EXAS · $85.8M cap vs rev $2.76B
Climb Bio Inc (CLYM) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Climb Bio Inc (CLYM) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
CLYM does not have a complete income-statement cache yet.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
CLYM currently screens at market cap $85.8M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the CLYM and EXAS stock pages for the full models.
Not investment advice.